Prevalence and risk factors of low bone mineral density among perinatally HIV-infected Thai adolescents receiving antiretroviral therapy

Thanyawee Puthanakit, MD[1,2], **Rachanee Saksawad, MD**[3], **Torsak Bunupuradah, MD**[2], **Orasi Wittawatmongkol, MD**[3], **Thongsuai Chuanjaroen, RN**[2], **Sasiwimol Ubolyam, Msc**[2], **Tawatchai Chaiwatanarat, MD**[4], **Pairunyar Nakavachara, MD**[3], **Alan Maleesatharn, MBA**[3], and **Kulkanya Chokephaibulkit, MD**[3,*]

[1]Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand 10330

[2]HIV-NAT/Thai Red Cross AIDS Research, 104 Ratchadamri Road, Pathumwan, Bangkok Thailand 10330

[3]Department of Pediatrics, Faculty of Medicine Siriraj Hospital, Mahidol University, 2, Prannok Road, Bangkok-Noi, Bangkok, Thailand, 10700

[4]Department of Radiology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand 10330

Abstract

Background—Low bone mineral density (BMD) has been reported among 10–54% of HIV-infected adolescents in developed countries. We studied the prevalence and predictors of low BMD among HIV-infected Thai adolescents receiving antiretroviral therapy.

Methods—A cross-sectional study of lumbar spine (L2–L4) BMD as measured by dual-energy X-ray absorptiometry (DXA) in Thai HIV-infected adolescents aged 12–20 years was performed. The BMD Z-score was analyzed using age-matched healthy Thai children as a reference. Serum 25-hydroxyvitamin D (25-OHD) was performed. Osteopenia was defined as BMD Z-score ≤ –2.

Results—From October 2010 to February 2011, 101 adolescents, 50% male, with a median age of 14.3 (range, 13.0–15.7) years were enrolled. The median (IQR) current CD4 T-cell count was 646 (506–796) cells/mm^3 and 90% had plasma HIV-1 RNA <50 copies/ml. The mean BMD among HIV-infected adolescents and controls were 0.855 and 0.980 g/cm^2(*P*<0.001). The median (IQR) L2–L4 spine BMD Z-score was −1.0 (−1.9 to −0.1), of which 24% had BMD Z-score ≤ −2.0. The median (IQR) of 25-OHD level was 24.8 (20.0–31.4) ng/ml, of which 25% had vitamin D level < 20 ng/ml. In multivariate analysis, the height for age Z-score <−1.5 (adjusted odds ratio (aOR) 6.2; 95% CI 2.2–17.7) and history of WHO clinical stage 4 prior to ART (aOR 3.7; 95%CI 1.3–10.7) were significantly associated with osteopenia.

Corresponding author: Dr. Kulkanya Chokephaibulkit., Division of Infectious Diseases, [3]Department of Pediatrics, Faculty of Medicine Siriraj Hospital, Mahidol University, 2, Prannok Road, Bangkok-Noi, Bangkok, Thailand, 10700. sikch@mahidol.ac.th Telephone: 662-4180545 Fax 662-4180544.

Conclusion—One-fourth of HIV-infected Thai adolescents have osteopenia. Children with history of advanced- staging or having low height for age are at risk of osteopenia. Preventive measures to prevent osteopenia should be incorporated in routine care for these adolescents.

Keywords

Bone mineral density; HIV-infected adolescents; vitamin D deficiency; osteopenia

Introduction

Antiretroviral therapy (ART) increases life expectancy of HIV-infected patients. However, many long term complications, including low bone mineral density (BMD), are concerning. A meta-analysis of HIV-infected adults showed that two-third of patients had low BMD, of whom 15% had osteoporosis[1]. In addition, the fracture rate in the HIV-infected population was 30–70% higher than uninfected control subjects[2]. Many studies reported lower bone mass in perinatally HIV-infected children and adolescents compared to healthy peers[3–6]. A study from the US showed that 20% of HIV-infected children had BMD Z-score < −1.5 at any site of measurement[7]. A great deal of accumulation of bone mass occurs during the adolescent years, and peak attainment is seen at age 18 [8, 9]. Therefore, loss of bone deposition during adolescence could lead to an increased risk of osteoporosis and fractures later of life[10].

The predictors of reduced BMD in HIV-infected adults are many and include traditional risk factors and HIV-related metrics. Traditional risk factors include older age, female sex, menopause, corticosteroid therapy, smoking, alcohol use, low calcium intake, low vitamin D level, limited physical activity, low body mass index (BMI) and white race[11]. HIV-related factors such as duration of HIV infection[12–14], uncontrolled viremia[2], and exposure to ART are also related. Antiretroviral drugs have variable effects on bone density. For example, protease inhibitors (PIs) are associated with reduced BMD and osteoporosis and tenofovir disoproxil fumarate (TDF) is associated with decreased bone mass[15–20].

Many factors related with lower peak bone mass in children including delayed growth and puberty, low lean body mass, hormone and inflammation cytokine, vitamin D deficiency, malabsorption and physical inactivity[6,8,9]. However, HIV-related factors are important contributing factors to bone loss in children such as advanced HIV disease, uncontrolled viremia, and specific ART [2,6.]

The objective of this study is to investigate the prevalence of low bone mass in HIV-infected Thai adolescents and characterize the associated risk factors in our populations. We conducted a cross-sectional study to measure the bone mineral density among HIV-infected adolescents using a dual-energy X-ray absorptiometry (DXA).

Materials and Methods

Participants

We performed a cross-sectional study to measure BMD in perinatally-HIV infected Thai adolescents aged 12–20 years who have been followed up at two referral centers in Bangkok, Siriraj and King Chulalongkorn Memorial hospitals from October 2010 to February 2011. As BMD may be affected by gender, ART regimens, and Tanner stage, we enrolled 10–15 subjects for each of eight strata: male or female, receiving protease inhibitor (PI) regimen or nonnucleoside reverse-transcriptase inhibitor (NNRTI) regimen, and Tanner stage 1–2 or 3–5. The exclusion criteria were having conditions that might affect bone mass such as endocrine disorders, renal impairment (serum creatinine > 2 mg/dl), liver

impairment (ALT > 100 IU/L) within 6 months prior to enrollment, underlying malignancy, and taking any non-ARV medications that probably impact bone mass such as corticosteroids or anticonvulsants. The protocol was approved by the institutional review boards at both centers. Written informed assent and consent were obtained from adolescents and their caregivers. The study procedure included physical examination, anthropometric measurement, Tanner stage evaluation, blood sample collection for 25-hydroxyvitamin D (25-OHD), intact parathyroid hormone level (iPTH), alkaline phosphatase (ALK), calcium, phosphorus, and DXA scanning. The clinical data collected from the medical record were WHO clinical stage prior to ART, HIV-1 RNA levels, CD4 T-cell count within the past 6 months, nadir CD4 T-cell count, and ART history. History of fracture was taken from direct questioning of participants and guardians.

The Z-score for weight for age (WAZ) and height for age (HAZ) was calculated based on Thai reference[21]. The BMI percentile was based on US-CDC reference[22]. The 25-OHD level and iPTH were measured by chemiluminescent microparticle immunoassay (ARCHITECT 25-OH vitamin D assay and ARCHITECT Intact PTH assay, Abbott Diagnostics Division, Wiesbaden, Germany). Vitamin D deficiency defined as 25-OHD level < 20 ng/ml[23]. The upper normal limit of serum iPTH was 65 pg/ml[24]. Serum calcium, phosphorus, and ALK were measured by the VITROS Ca Slide method, VITROS PHOS Slide method, and VITROS ALKP Slide method (Ortho-Clinical Diagnostics Inc., Rochester, New York, USA), respectively. The normal range of calcium and phosphorus were 8.6–10.0 mg/dl and 4.0–7.0 mg/dl, respectively. The normal range of alkaline phosphatase level for male and female were 100–390 U/L and 100–320 U/L, respectively.

Dual-energy X-ray absorptiometry (DXA) and interpretation

BMD was evaluated by DXA scanners, Lunar Prodigy (General Electric Healthcare, Madison, Wisconsin, USA) at Siriraj hospital and Hologic Discovery A (Hologic, Inc., Bedford, Massachusetts, USA) at King Chulalongkorn Memorial Hospital. The scanner machines were calibrated on a daily basis according to the manufacturer's instructions. The subjects were scanned at the second to fourth lumbar spines (L2–L4).

We compared the bone mineral density data of HIV-infected adolescents with data from a cohort of 199 HIV-negative aged from 12–18 years measured by Lunar Prodigy scanner. The inclusion criteria of healthy control was adolescent who has weight and height within 2 standard deviation from Thai normative data, has no underlying disease, and does not receive medications that may affect BMD such as glucocorticoid. At least 10 children per gender per year of age from 12–18 years old were enrolled at Siriraj hospital. Mean (SD) weight for age and height for age Z-score of control were 0.2 (0.8) and 0.2 (1.0), respectively. For adolescents who reached 18 years of age, the Thai adult normative reference was used[25].

Because of variations in BMD values measured by different machines and the normative reference BMD were available only by Lunar scanner, the BMD values measured by Hologic scanner were converted to the values measured by Lunar scanner using the equation previously published (*GE-Lunar=1.195×Hologic–0.023)* [26] before calculating Z-score. This equation was developed from the Hologic Delphi (using Hologic Apex software) and GE-Lunar Prodigy DXA systems (using GE-Lunar EnCore software). Before adopting this equation, our first 15 adolescents were scanned by both machines. We then compared the results of BMD from Lunar with the converted BMD from Hologic scanner, using the equation, and found no difference (*P*=0.669). The limits of agreement between 2 scanner types was −0.062 to 0.074 (*P*=0.861) by Bland -Altman analysis. The BMD Z-score was calculated based on the reference values for normal Thai adolescents using the equation: $BMD\ Z\text{-score} = (BMD_{measured} - BMD_{reference\ for\ age\ and\ sex})/SD_{reference\ for\ age\ and\ sex}.$

According to International Society for Clinical Densitometry (ISCD), low BMD was defined as spine BMD Z-score less than or equal to −2.0 [27].

Statistical analysis

Descriptive analysis of BMD among HIV-infected adolescents was stratified by age and gender. BMD values and BMD Z-score of HIV-infected adolescents were compared with normal healthy Thai adolescents by Student *t*-test. Categorical variables were compared between the adolescents with BMD Z-score −2 and >−2.0 by the chi-square test or Fisher exact test as appropriate. Continuous variables were compared by the Mann-Whitney rank sum test, Student *t*-test or One-Way ANOVA analysis as appropriate. Univariate logistic regression was performed to evaluate the association between reported factors related to osteopenia including body mass index, weight for age Z-score, height for age Z-score, tanner stage, WHO staging, antiretroviral therapy regimen, HIV-1 RNA level, and vitamin D level. Multivariate analyses for factors associated with low BMD were performed by stepwise logistic regression model including factors that had p-value less than 0.2 in univariate analyses. Data were analyzed with the IBM SPSS Statistics 20.0.

Results

Demographic characteristics

One hundred and one perinatally HIV-infected adolescents, median (interquartile range; IQR) age 14.3 years (13.0–15.7), were enrolled. The demographic characteristics are shown in Table 1. The mean duration of ART was 83.9 (52.2–104.2) months. The current ART regimens were 50% NNRTI-based, 48%PI-based, and 2% NNRTI plus PI-based. Fifteen (14.9%) adolescents have received TDF for mean duration of 10 months. The median (IQR) current CD4 T-cell count was 646 (506–796) cells/mm^3 and 90% had plasma HIV-1 RNA < 50 copies/ml. Twenty-eight adolescents had history of WHO stage 4 prior to receiving ART.

Bone mineral density at lumbar spine among HIV-infected children

The BMD data from 98 HIV-infected adolescents (not including 3 children older than 18 years of age) were compared with 199 HIV-negative age-matched healthy Thai adolescent controls. The mean BMD among HIV-infected adolescents and HIV-negative controls were 0.855 and 0.980 g/cm^2, respectively (P< 0.001). HIV-infected adolescents generally had lower spine BMD than healthy Thai adolescents controls across age and gender strata (Figure 1). The mean (SD) L2–L4 spine BMD Z-score among 101 HIV-infected adolescents was −0.9 (1.4), P< 0.001 compared to zero z-score. The proportion of HIV-infected adolescents with BMD Z-score −1.5, −2.0, and −2.5 were 36 %, 24 % and 11 %, respectively. Proportion of adolescents with BMD Z-score 2.0 were 23.5% and 24% among children who performed BMD by Hologic and Lunar scanner, respectively (P=0.956). There was no report of fracture history.

Vitamin D level and laboratory tests related to bone metabolisms

Vitamin D level and laboratory test related to bone metabolisms are shown in table 2. The median (IQR) 25-OHD level was 24.8 (20.0–31.4) ng/ml and 25% had vitamin D deficiency which defined as vitamin D level < 20 ng/ml. Median (IQR) iPTH level was 44.0 (36.4–58.7) pg/ml and 19% had iPTH level higher than upper normal limit of 65 pg/ml. Among the 25 adolescents with vitamin D deficiency, 44% had high iPTH compared to only 10% in those without vitamin D deficiency (P<0.001). The median (IQR) iPTH level was higher in adolescents with vitamin D deficiency (54.9 (38–77) vs. 40.2 (32.6–54.9, P=0.007).

Associated factors related to low bone mineral density for age

In univariate analyses, body mass index below 5 percentile, weight for age Z-score below −1.5, height for age Z-score below < −1.5 and history of WHO clinical stage 4 prior to ART were associated with low BMD (table 3). In multivariate analysis, only HAZ <−1.5 (adjusted odds ratio (aOR) 6.19; 95%CI 2.17–17.69; P=0.001) and WHO clinical stage 4 prior to ART (aOR 3.67; 95%CI 1.26–10.67.88, P=0.017) were independently associated with low BMD.(Table 3)

Discussion

Our study is the first study of bone mineral density in HIV-infected adolescents in Asian populations. We found one-fourth of HIV-infected Thai adolescents had low BMD. The HAZ <−1.5 and WHO clinical stage 4 prior to ART are associated with low BMD.

In this study, we found that, of Thai HIV-infected adolescents, 36% and 24% had bone mineral density for age Z-scores −1.5 and −2.0, respectively. This was higher than 10.6% reported spine BMD Z-score −1.5 in HIV-infected children and adolescents in the US[7]. Interpretation of BMD results should be based on the normative databases by gender, age, race/ethnicity, and should be specific for each manufacturer and model of densitometer and software[27]. In this study we addressed these potential confounders by comparing BMD data with data from Thai HIV-negative adolescent database and by using conversion factor to address for the differences between Lunar and Hologic machines. The results of BMD Z-score −2.0 in our study would have been as high as 43% if we used the Z-score reported by the machines using its installed software with normative reference from other ethnic groups. The International Society for Clinical Densitometry (ISCD) suggested that the BMD interpretation should be adjusted for absolute height or height age in children with linear growth or maturational delay[27]. Zemel B et al studied various methods to adjust BMD for height including using height age, and height for age Z-score adjustment equations[28]. The study suggested that substituting height age for chronological age as a means of adjusting for short stature was not a good approach because the children who are short for age will be compared with children of similar height who are younger and at an earlier stage of sexual maturation. The study proposed that using height for age Z-score adjustment equation was the least bias method. Unfortunately, the equations were developed for healthy US children based on Hologic systems, which can not apply to our study. Therefore, the higher rate of low BMD in our study compared to US data may be partly attributable to an inability to correct the effect of short stature on bone mineral density Z-score calculation.

We found WHO clinical stage 4 prior to ART and HAZ < −1.5 to be associated with low bone mass. The study in HIV-infected adults also found advanced clinical stage of HIV disease associated with higher risk for low bone mass [29]. Advanced HIV disease prior to ART resulting in poor growth may be the major factor of low bone mass in our adolescent population. The association between HAZ < −1.5 and low bone mass may be a true association due to low height-age reflecting a poor long term health status or may be confounded by an inability to correct the effect of short stature on bone mineral density Z-score calculation. Other factors reportedly associated with low BMD were low BMI and uncontrolled HIV-1 RNA[7, 15, 16, 30]. Many studies found an association between low bone mass with PI [1, 6, 7, 15, 29, 31] and TDF use [15–20, 32–34]. We found lower spine BMD Z-scores among HIV-infected adolescents receiving PI but not reached statistical significance in multivariate analysis. We found no association with the use of TDF and low bone mass, this probably due to short period of TDF exposure in this cohort with mean exposure of 10.0 months.

Several studies have reported high rates of vitamin D deficiency in HIV-infected individuals, ranging from 23–92%[35]. The vitamin D level in HIV-infected adults in the US, whether on ART or not, was also lower than in the uninfected population[29]. The prevalence of vitamin D deficiency in children and adolescents varies from 0–42% depending on season, latitude, and ethnicity[35]. A previous study in Thailand found none of the 600 Thai healthy children and adolescents (aged 9–18 years) had vitamin D deficiency (in process of publication). We found 25% of HIV-infected adolescents had vitamin D deficiency (< 20 ng/ml). Vitamin D deficiency may play role for lower bone mass in HIV-infected children. Fifty percent of HIV-infected children in the US, and 30% of adolescents in our cohort with BMD Z-score <−1.5 had low levels of 25-OHD[7]. HIV-infected children were in chronic illness condition and may have less habit of sun-exposure particularly in the tropical countries. These children also have poorer nutritional status and lower intake of vitamin containing food. HIV-infected patients may have impaired 1α-hydroxylation that decreases production and action of the active vitamin D metabolite $1,25(OH_2D_3)$ despite normal vitamin D levels[36]. Some ART such as PI and efavirenz, suppress the activity of 25 and 1α-hydroxylase or activates the destruction of 25-OHD and $1,25(OH_2D_3)$ to inactivate calcitroic acid[23, 29]. Higher rate of vitamin D deficiency may be explained by exposure to antiretroviral drugs especially efavirenz [37] On the other hand, PTH levels could be lower than expected in HIV-infected patients because PTH secretion is inhibited by pro-inflammatory cytokines[29, 36] and PTH resistance has been reported in HIV infection[36]. ART also altered the PTH secretion in both directions [29, 34, 38]. These findings suggested alteration of vitamin D and PTH system in HIV-infection, which may affect bone health. However, we found no association between low BMD and vitamin D deficiency. Taken together, our findings suggest that BMD in our adolescents is affected by factors other than low vitamin D. An alternate theory, previous data demonstrated pro-inflammatory cytokines such as interleukin-6, elevated in HIV patients, adversely affecting BMD[36, 39].

Most of HIV-infected patients had normal serum calcium[29]. Similar to other studies, we did not find association between serum calcium and bone mass[7, 40]. Interestingly, we found phosphorus levels higher in the adolescents with low BMD, however, the levels found were mostly within normal range, and not reached statistical significance in the multivariate analysis. The ALK is not a sensitive or specific index of pathology in osteoporosis[41] and was not found to associated with BMD. The bone specific alkaline phosphatase (BAP), on the other hand, is more sensitive and specific for bone formation[41]. Serum BAP was found to be elevated in HIV-infected children and adults suggesting high bone turnover state, especially in the patients receiving TDF [4, 12, 17, 29, 33, 34]. The bone metabolic markers may not be useful for a cross sectional study as alteration of these markers may no longer exist while the decreased bone mass from previous long-term process was still evident.

Our study had several limitations. It was cross-sectional and so unable to evaluate the change of bone mass over a period of treatment. Prospective longitudinal study is therefore warranted. The use of different scanners between the two study sites may cause variability of the results despite the conversion formula. The fact that the adolescents in our cohort had been taking ART for an extended period of time, it is not possible to evaluate acute effect of initiation of ART on BMD. Many adolescents had experienced various ART regimens and therefore our ability to evaluate the impact of specific antiretroviral medications was limited.

In conclusion, we found low bone mass in a quarter of HIV-infected Thai adolescents. Poor growth and advanced HIV stage before ART were the independent associated risk factors. The results of this study underscored the importance of early ART initiation to preserve growth and bone health in children.

Acknowledgments

References

1. Brown TT, Qaqish RB. Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS. 2006; 20:2165–2174. [PubMed: 17086056]

2. McComsey GA, Tebas P, Shane E. Bone disease in HIV infection: a practical review and recommendations for HIV care providers. Clin Infect Dis. 2010; 51:937–946. [PubMed: 20839968]

3. O'Brien KO, Razavi M, Henderson RA, et al. Bone mineral content in girls perinatally infected with HIV. Am J Clin Nutr. 2001; 73:821–826. [PubMed: 11273859]

4. Mora S, Zamproni I, Beccio S, et al. Longitudinal changes of bone mineral density and metabolism in antiretroviral-treated human immunodeficiency virus-infected children. J Clin Endocrinol Metab. 2004; 89:24–28. [PubMed: 14715822]

5. Jacobson DL, Spiegelman D, Duggan C, et al. Predictors of bone mineral density in human immunodeficiency virus-1 infected children. J Pediatr Gastroenterol Nutr. 2005; 41:339–346. [PubMed: 16131991]

6. Jacobson DL, Lindsey JC, Gordon CM, et al. Pediatric AIDS Clinical Trials Group P1045 team. Total body and spinal bone mineral density across Tanner stage in perinatally HIV-infected and uninfected children and youth in PACTG 1045. AIDS. 2010; 24:687–696. [PubMed: 20168204]

7. Jacobson, DL.; DiMeglio, LA.; Hazra, R., et al. Clinical determinants of bone mineral density (BMD) in perinatally HIV-infected children [911]. Presented at: the 16th Conference on Retroviruses and Opportunistic Infections; 2009; Montreal.

8. Theintz G, Buchs B, Rizzoli R, et al. Longitudinal monitoring of bone mass accumulation in healthy adolescents: evidence for a marked reduction after 16 years of age at the levels of lumbar spine and femoral neck in female subjects. J Clin Endocrinol Metab. 1992; 75:1060–1065. [PubMed: 1400871]

9. Soyka LA, Fairfield WP, Klibanski A. Clinical review 117: hormonal determinants and disorders of peak bone mass in children. J Clin Endocrinol Metab. 2000; 85:3951–3963. [PubMed: 11095413]

10. Hansen MA, Overgaard K, Riis BJ, et al. Role of peak bone mass and bone loss in postmenopausal osteoporosis: 12 year study. BMJ. 1991; 303:961–964. [PubMed: 1954420]

11. Mallon PW. HIV and bone mineral density. Curr Opin Infect Dis. 2010; 23:1–8. [PubMed: 20010102]

12. Mondy K, Yarasheski K, Powderly WG, et al. Longitudinal evolution of bone mineral density and bone markers in human immunodeficiency virus-infected individuals. Clin Infect Dis. 2003; 36:482–490. [PubMed: 12567307]

13. Dolan SE, Kanter JR, Grinspoon S. Longitudinal analysis of bone density in human immunodeficiency virus-infected women. J Clin Endocrinol Metab. 2006; 91:2938–2945. [PubMed: 16735489]

14. Bruera D, Luna N, David DO, et al. Decreased bone mineral density in HIV-infected patients is independent of antiretroviral therapy. AIDS. 2003; 17:1917–1923. [PubMed: 12960824]

15. Bonjoch A, Figueras M, Estany C, et al. High prevalence of and progression to low bone mineral density in HIV-infected patients: a longitudinal cohort study. AIDS. 2010; 24:2827–2833. [PubMed: 21045635]

16. Jacobson DL, Spiegelman D, Knox TK, et al. Evolution and predictors of change in total bone mineral density over time in HIV-infected men and women in the nutrition for healthy living study. J Acquir Immune Defic Syndr. 2008; 49:298–308. [PubMed: 18845956]

17. Calmy A, Fux CA, Norris R, et al. Low bone mineral density, renal dysfunction, and fracture risk in HIV infection: a cross-sectional study. J Infect Dis. 2009; 200:1746–1754. [PubMed: 19874178]

18. McComsey GA, Kitch D, Daar ES, et al. Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG A5202. J Infect Dis. 2011; 203:1791–1801. [PubMed: 21606537]

19. Stellbrink HJ, Orkin C, Arribas JR, et al. Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study. Clin Infect Dis. 2010; 51:963–972. [PubMed: 20828304]

20. Martin A, Bloch M, Amin J, et al. Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-lamivudine: a randomized, 96-week trial. Clin Infect Dis. 2009; 49:1591–1601. [PubMed: 19842973]

21. Working Group on Using Weight and Height References in Evaluating the Growth Status of Thai Children. Manual on Using Weight and Height References in Evaluation in Growth Status of Thai Children. Bangkok: Department of Health, Ministry of Public Health; 2000.

22. Centers for disease control and prevention. BMI percentile calculator for child and teen english version. Available at: http://apps.nccd.cdc.gov/dnpabmi/

23. Holick MF. Vitamin D deficiency. N Engl J Med. 2007; 357:266–281. [PubMed: 17634462]

24. Esoterix Laboratory Services Inc. Expected values and SI Unit conversion pocket book (monograph online). Available at: http://www.esoterix.com/files/expected_values.pdf

25. Sriussadaporn SSN, Ploybutr S, Tanlakij M, et al. Assessment, of bone mineral density and factors influencing bone mineral density in Thalassemic diseases in Thailand; 2000. Report to the National Research Council of Thailand.

26. Fan B, Lu Y, Genant H, et al. Does standardized BMD still remove differences between Hologic and GE-Lunar state-of-the-art DXA systems? Osteoporos Int. 2010; 21:1227–1236. [PubMed: 19859644]

27. Gordon CM, Bachrach LK, Carpenter TO, et al. Dual energy X-ray absorptiometry interpretation and reporting in children and adolescents: the 2007 ISCD Pediatric Official Positions. J Clin Densitom. 2008; 11:43–58. [PubMed: 18442752]

28. Zemel BS, Leonard MB, Kelly A, et al. Height adjustment in assessing dual energy x-ray absorptiometry measurements of bone mass and density in children. J Clin Endocrinol Metab. 2010; 95:1265–1273. [PubMed: 20103654]

29. Madeddu G, Spanu A, Solinas P, et al. Bone mass loss and vitamin D metabolism impairment in HIV patients receiving highly active antiretroviral therapy. Q J Nucl Med Mol Imaging. 2004; 48:39–48. [PubMed: 15195003]

30. Bolland MJ, Grey AB, Gamble GD, et al. CLINICAL Review: low body weight mediates the relationship between HIV infection and low bone mineral density: a meta-analysis. J Clin Endocrinol Metab. 2007; 92:4522–4528. [PubMed: 17925333]

31. Zuccotti G, Viganò A, Gabiano C, et al. Antiretroviral therapy and bone mineral measurements in HIV-infected youths. Bone. 2010; 46:1633–1638. [PubMed: 20211284]

32. Hazra R, Gafni RI, Maldarelli F, et al. Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy for pediatric HIV infection. Pediatrics. 2005; 116:e846–854. [PubMed: 16291735]

33. Purdy JB, Gafni RI, Reynolds JC, et al. Decreased bone mineral density with off-label use of tenofovir in children and adolescents infected with human immunodeficiency virus. J Pediatr. 2008; 152:582–584. [PubMed: 18346519]

34. Gafni RI, Hazra R, Reynolds JC, et al. Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy: impact on bone mineral density in HIV-infected children. Pediatrics. 2006; 118:e711–718. [PubMed: 16923923]

35. Huh SY, Gordon CM. Vitamin D deficiency in children and adolescents: epidemiology, impact and treatment. Rev Endocr Metab Disord. 2008; 9:161–170. [PubMed: 18175220]

36. Kühne CA, Heufelder AE, Hofbauer LC. Bone and mineral metabolism in human immunodeficiency virus infection. J Bone Miner Res. 2001; 16:2–9. [PubMed: 11149485]

37. Dao CN, Patel P, Overton ET, et al. Low vitamin D among HIV-infected adults: prevalence of and risk factors for low vitamin D levels in a cohort of HIV-infected adults and comparison to prevalence among adults in the US general population. Clin Infect Dis. 2011; 52:396–405. [PubMed: 21217186]

38. van Vonderen MG, Lips P, van Agtmael MA, et al. First line zidovudine/lamivudine/lopinavir/ritonavir leads to greater bone loss compared to nevirapine/lopinavir/ritonavir. AIDS. 2009; 23:1367–1376. [PubMed: 19424051]

39. Arpadi S, Horlick M, Shane E. Metabolic bone disease in human immunodeficiency virus-infected children. J Clin Endocrinol Metab. 2004; 89:21–23. [PubMed: 14715821]

40. Ramayo E, González-Moreno MP, Macías J, et al. Relationship between osteopenia, free testosterone, and vitamin D metabolite levels in HIV-infected patients with and without highly active antiretroviral therapy. AIDS Res Hum Retroviruses. 2005; 21:915–921. [PubMed: 16386106]

41. Camozzi, V.; Moro, L.; Luisetto, G., et al. Bone turnover markers in clinical practice and their potencial use in HIV-related bone disease. HAART and correlated pathologies. 2009. Available at: http://www.mnlpublimed.com/public/HA02-A01.pdf

Figure 1.
Lumbar spine bone mineral density of HIV-infected Thai adolescents compared with healthy controls

Table 1

Demographic characteristics among 101 HIV-infected adolescents

Characteristics	Total (N=101)	Adolescents with BMD Z-score > −2.0 (N=77)	Adolescents with BMD Z score −2.0 (N=24)	*P* value
Male	51 (50.5)	39 (50.6)	12 (50.0)	0.956[a]
Age, years	14.3 (13.0–15.7)	14.3 (13.0–15.7)	14.1 (13.0–16.2)	0.870[b]
Body mass index, kg/m²	17.7 (16.2–19.9)	18.0 (16.5–20.7)	17.0 (14.8–18.5)	0.033[b]
< 5 percentile	26 (25.7)	15 (19.5)	11 (45.8)	**0.010**[a]
Thai weight for age Z-score (WAZ)	−0.8 (−1.7 to 0.2)	−0.6 (−1.3 to 0.4)	−1.9 (−2.3 to − 0.9)	**<0.001** [b]
WAZ < −1.5	29 (28.7)	14 (18.2)	15 (62.5)	**<0.001**[a]
Thai height for age Z-score (HAZ)	−0.9 (−1.8 to −0.3)	−0.7 (−1.4 to −0.1)	−1.8 (−2.4 to −1.3)	**<0.001** [b]
HAZ < −1.5	33 (32.7)	17 (22.1)	16 (66.7)	**<0.001** [a]
Tanner stage				
Stage 1–2	32 (31.7)	21 (27.3)	11 (45.8)	0.088[a]
Stage 3–5	69 (68.3)	56 (72.7)	13 (54.2)	
Duration of ART, months	83.9 (52.2–104.2)	88.2 (62.0–105.9)	56.4 (36.5–88.0)	**0.026**[b]
Duration of ART by regimen type, months				
NRTI	82.9 (43.8–102.9)	84.9 (46.5–106.8)	53.6 (28.6–89.3)	0.065[b]
NNRTI	54.0 (29.9–88.7)	60.5 (37.3–90.3)	46.7 (24.5–53.8)	**0.041**[b]
PI	44.8 (33.2–76.3)	54.9 (33.2–79.2)	40.8 (32.4–63.1)	0.260[b]
Current ART regimens				
NNRTI-based	50 (49.5)	41 (53.2)	9 (37.5)	0.143[a, #]
PI-based	49 (48.5)	34 (44.2)	15 (62.5)	
both NNRTI and PI-based	2 (2.0)	2 (2.6)	-	
Receiving TDF	15 (14.9)	13 (16.9)	2 (8.3)	0.511[c]
Current CD4 T-cell count, cells/mm³	646 (506–796)	628 (486–804)	717 (556–801)	0.181[b]
Nadir CD4 T-cell count, cells/mm³	114 (31–226)	134 (28–245)	99 (38–184)	0.814[b]
Proportion with plasma HIV-1 RNA viral load < 50 copies/ml	91 (90.1)	71 (92.3)	20 (83.3)	0.243[c]
WHO clinical stage prior to ART				
Stage 1–2	34 (33.7)	30 (39.0)	4 (16.7)	0.527[c, †]
Stage 3	39 (38.6)	32 (41.5)	7 (29.2)	
Stage 4	28 (27.7)	15 (19.5)	13 (54.2)	**0.004**[c, ‡]

NOTE: Continuous data presented in median(IQR). Categorical data presented in n(%).

[a]χ^2 test,

[b]Mann-Whitney rank sum test,

[c]Fisher's exact test

[#]compare between NNRTI-based and PI-based regimen,

[†]compare between WHO clinical stage 3 and stage 1–2,

[‡]compare between WHO clinical stage 4 and stage 1–2

ART, antiretroviral therapy; NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, nonnucleoside reverse transcriptase inhibitor; PI, protease inhibitor; TDF, tenofovir disoproxil fumarate

Table 2

Vitamin D level and laboratory results related to bone metabolism among HIV-infected adolescents

Characteristics	Total (N=101)	Adolescents with BMD Z-score > −2.0 (N=77)	Adolescents with BMD Z score −2.0 (N=24)	*P* value
25-hydroxyvitamin D level, ng/ml	24.8 (20.0–31.4)	24.9 (20.0–30.5)	24.4 (17.7–31.9)	0.618[a]
Level < 20 ng/ml	25 (24.8)	18 (23.4)	7 (29.2)	0.566[b]
Parathyroid hormone level, pg/ml	44.0 (36.4–58.7)	44.0 (34.6–60.1)	40.0 (29.7–52.8)	0.271[a]
Level > 65 pg/ml	19 (18.8)	16 (20.8)	3 (12.5)	0.551[c]
Alkaline phosphatase level, U/L	198.0 (135.0–282.5)	172.0 (130.0–278.0)	234.5 (152.0–295.5)	0.125[a]
Calcium level, mg/dl	9.7 (9.5–10.0)	9.7 (9.6–10.0)	9.8 (9.4–10.0)	0.718[a]
Phosphorus level, mg/dl	4.6 (4.2–5.2)	4.5 (4.1–5.1)	5.1 (4.3–5.6)	**0.022[a]**

NOTE: Continuous data presented in median(IQR). Categorical data presented in n(%).

[a]Mann-Whitney rank sum test,

[b]χ^2 test,

[c]Fisher's exact test

Table 3

Factors associated with osteopenia (defined as lumbar spine 2nd–4th bone mineral density Z-score ≤ −2.0)

Characteristics	Univariable analysis		Multivariable analysis	
	Odds ratio (95% CI)	*P* value	Adjusted odds ratio (95%CI)	*P* value
Body mass index below 5 percentile	3.50 (1.31–9.33)	0.012	-	**-**
Weight for age Z-score below −1.5	7.50 (2.73–20.57)	< 0.001	-	**-**
Height for age Z-score below −1.5	7.06 (2.58–19.29)	<0.001	6.19 (2.17–17.69)	0.001
Tanner stage 1–2 (vs. stage 3–5)	2.26 (0.88–5.82)	0.092	-	-
WHO clinical classification prior to ART				
Stage 4 (vs. non stage 4)	4.89 (1.83–13.03)	0.002	3.67 (1.26–10.67)	0.017
Current ART regimen (PI vs. NNRTI)	2.01 (0.78–5.16)	0.147	-	**-**
Duration of tenofovir (month)	0.92 (0.77–1.09)	0.325	-	**-**
Current plasma HIV-1 RNA < 50 copies/ml	0.42 (0.11–1.64)	0.214	-	**-**
25-hydroxyvitamin D level				
< 20 ng/ml (vs. ≥ 20 ng/ml)	1.35 (0.48–3.77)	0.567	-	-

NOTE: ART, antiretroviral therapy; PI, protease inhibitors; NNRTI, non-nucleoside reverse transcriptase inhibitor